User:Mr. Ibrahem/Ozanimod

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ozanimod
Clinical data
Trade namesZeposia
Other namesRPC-1063
AHFS/Drugs.comMonograph
MedlinePlusa620029
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classsphingosine-1-phosphate|S1P blocker[2][3]
Legal status
Legal status
Pharmacokinetic data
Elimination half-life19 hours
Identifiers
  • 5-(3-{(1S)-1-[(2-Hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile
Chemical and physical data
FormulaC23H24N4O3
Molar mass404.470 g·mol−1
3D model (JSmol)
  • CC(C)Oc1ccc(cc1C#N)c2nc(no2)c3cccc4c3CC[C@@H]4NCCO
  • InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
  • Key:XRVDGNKRPOAQTN-FQEVSTJZSA-N

Ozanimod, sold under the brand name Zeposia, is a medication used to treat multiple sclerosis (MS) and ulcerative colitis (UC).[2][3] For MS this includes clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease.[3] In UC it is used in those with moderate to severe disease.[3] It is taken by mouth.[3]

Common side effects include upper respiratory infection, liver inflammation, low blood pressure with standing, urinary tract infection, and back pain.[3] Other side effects may include heart arrhythmias, high blood pressure, and macular edema.[3] Use during or in the 3 months before pregnancy may harm the baby.[3] It is a sphingosine-1-phosphate (S1P) receptor agonist, which results in stopping lymphocytes from going to the brain and spinal cord.[2][3]

Ozanimod was approved for medical use in the United States, Europe, and Australia in 2020.[2][3][5] In the United Kingdom 4 weeks of medication costs the NHS about £1,400 as of 2021.[6] In the United States this amount costs about 7,200 USD.[7]

References[edit]

  1. ^ a b "Zeposia Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 27 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
  2. ^ a b c d e f "Zeposia EPAR". European Medicines Agency. 26 March 2020. Archived from the original on 25 October 2020. Retrieved 17 August 2020.
  3. ^ a b c d e f g h i j k l m "DailyMed - ZEPOSIA- ozanimod hydrochloride capsule ZEPOSIA 7-DAY STARTER PACK- ozanimod hydrochloride kit ZEPOSIA STARTER KIT- ozanimod hydrochloride kit". dailymed.nlm.nih.gov. Archived from the original on 10 November 2021. Retrieved 10 November 2021.
  4. ^ "Zeposia (ozanimod) capsules, for oral use" (PDF). Celgene Corporation. 25 March 2020. Archived (PDF) from the original on 26 March 2020. Retrieved 26 March 2020.
  5. ^ Australian Public Assessment Report: Ozanimod hydrochloride (PDF) (Report). 25 November 2020. Archived (PDF) from the original on 4 June 2021. Retrieved 4 June 2021.
  6. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 902. ISBN 978-0857114105.
  7. ^ "Zeposia Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 10 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ozanimod&oldid=1205737444"